JP2016514727A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514727A5
JP2016514727A5 JP2016504377A JP2016504377A JP2016514727A5 JP 2016514727 A5 JP2016514727 A5 JP 2016514727A5 JP 2016504377 A JP2016504377 A JP 2016504377A JP 2016504377 A JP2016504377 A JP 2016504377A JP 2016514727 A5 JP2016514727 A5 JP 2016514727A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016504377A
Other languages
English (en)
Japanese (ja)
Other versions
JP6360881B2 (ja
JP2016514727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/031442 external-priority patent/WO2014153509A1/en
Publication of JP2016514727A publication Critical patent/JP2016514727A/ja
Publication of JP2016514727A5 publication Critical patent/JP2016514727A5/ja
Application granted granted Critical
Publication of JP6360881B2 publication Critical patent/JP6360881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016504377A 2013-03-22 2014-03-21 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ Active JP6360881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804314P 2013-03-22 2013-03-22
US61/804,314 2013-03-22
PCT/US2014/031442 WO2014153509A1 (en) 2013-03-22 2014-03-21 Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase

Publications (3)

Publication Number Publication Date
JP2016514727A JP2016514727A (ja) 2016-05-23
JP2016514727A5 true JP2016514727A5 (enExample) 2017-04-27
JP6360881B2 JP6360881B2 (ja) 2018-07-18

Family

ID=51581522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016504377A Active JP6360881B2 (ja) 2013-03-22 2014-03-21 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ

Country Status (6)

Country Link
US (2) US9724354B2 (enExample)
EP (1) EP2976086B1 (enExample)
JP (1) JP6360881B2 (enExample)
CN (1) CN105209042B (enExample)
CA (1) CA2907726A1 (enExample)
WO (1) WO2014153509A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297192A (en) 2016-04-15 2022-12-01 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
SMT202200348T1 (it) 2016-04-15 2022-11-18 Cancer Research Tech Ltd Composti eterociclici come inibitori della chinasi ret
ITUA20164278A1 (it) * 2016-06-10 2017-12-10 International Soc For Drug Development S R L COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
WO2022104206A1 (en) * 2020-11-13 2022-05-19 Neuron23, Inc. Kinase modulators and methods of use thereof
CN112782402A (zh) * 2020-12-11 2021-05-11 南京市儿童医院 一种利用mk-5108阻断aurka来减轻肾纤维化的方法

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU711592B2 (en) 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
TW486480B (en) 1996-03-08 2002-05-11 Zeneca Ltd Azolobenzazepine derivatives and compositions and method of use thereof
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
WO1998035048A2 (en) 1997-02-07 1998-08-13 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
RU2198885C2 (ru) 1997-09-29 2003-02-20 Мейдзи Сейка Кайся Лтд. Производные трициклического триазолобензазепина, способы их получения, фармацевтическая композиция и способ лечения аллергических заболеваний, промежуточные соединения и способы их получения
US6251689B1 (en) 1998-05-14 2001-06-26 Telik, Inc. Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof
NZ508314A (en) 1998-06-02 2004-03-26 Osi Pharm Inc Pyrrolo[2,3d]pyrimidine compositions and their use
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6624119B1 (en) 1998-11-16 2003-09-23 Basf Aktiengesellschaft 3-[Benz(ox/thi)azol-7-yl]-1h-pyrimidine-2,4-diones
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CN101259270A (zh) 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
IL148718A0 (en) 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001072299A1 (en) 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
AU2003225933A1 (en) 2002-03-22 2003-10-13 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
CA2558109A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
CA2557575A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
RS50568B8 (sr) 2004-05-14 2019-08-30 Millennium Pharm Inc Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
WO2006091897A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
CA2605435A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006283940A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
KR20080039438A (ko) 2005-08-25 2008-05-07 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
JP2009510066A (ja) 2005-09-29 2009-03-12 ワイス 血管運動症状（ｖｍｓ）の治療のためのモノアミン再取り込みのモジュレータである１−（１ｈ−インドール−１−イル）−３−（メチルアミノ）−１−フェニルプロパン−２−オール誘導体および関連の化合物
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
WO2007079164A2 (en) 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
TW200738725A (en) 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
CA2645137A1 (en) 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
HRP20160990T1 (hr) 2006-03-24 2016-10-07 Biogen Hemophilia Inc. Pc5 kao enzim obrade faktor ix propeptida
JP2009531443A (ja) 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
DE102006020327A1 (de) 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
EP2037919A2 (en) 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
DE602007005139D1 (de) 2006-07-21 2010-04-15 Novartis Ag Formulierungen für benzimidazolylpyridylether
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
EP1900729A1 (en) 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
EP2077850A2 (en) 2006-10-31 2009-07-15 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
MX2010001745A (es) 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Imidazoles fusionados para el tratamiento del cancer.
NZ585460A (en) 2007-11-13 2013-02-22 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US20110212157A1 (en) 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
MX2011006725A (es) * 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CA2764983A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
AR077974A1 (es) 2009-08-28 2011-10-05 Takeda Pharmaceutical Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
CN102770024A (zh) 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2016514727A5 (enExample)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2015500884A5 (enExample)
JP2014503574A5 (enExample)
JP2015532295A5 (enExample)
JP2015511638A5 (enExample)
JP2019502763A5 (enExample)
JP2015520143A5 (enExample)
JP2019500352A5 (enExample)
JP2020514311A5 (enExample)
RU2016134751A (ru) Соединения
JP2017524702A5 (enExample)
JP2014500295A5 (enExample)
JP2015537020A5 (enExample)
JP2016509047A5 (enExample)
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
JP2008535902A5 (enExample)
JP2012513390A5 (enExample)
RU2015124002A (ru) Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы
JP2017527532A5 (enExample)
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2016513696A5 (enExample)
JP2016515628A5 (enExample)